Company: ZVRA
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001628280-25-039967
Chunk: 73

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-08-12
Form: 10-Q
Item: Part I, Item 1
Chunk 73
---
3)CVR liability$1,370 $— $— $1,370 Warrant liabilities15,807 — — 15,807 Total liabilities$17,177 $— $— $17,177 Securities:U.S. Treasury securities$124,715 $124,715 $— $— Corporate bonds45,273 — 45,273 — Total assets$169,988 $124,715 $45,273 $— Balance as of December 31, 2024Quoted Prices in ActiveMarkets for Identical Assets(Level 1)Significant Other ObservableInputs (Level 2)Significant UnobservableInputs (Level 3)CVR liability$3,500 $— $— $3,500 Warrant liabilities17,804 — — 17,804 Total liabilities$21,304 $— $— $21,304 Securities:U.S. Treasury securities$35,711 $35,711 $— $— Corporate bonds6,010 — 6,010 — Total assets$41,721 $35,711 $6,010 $— 

22

WarrantsThe common stock warrant liabilities were recorded at fair value using the BSM option pricing model. The following assumptions were used in determining the fair value of the warrant liabilities valued using the BSM option pricing model as of June 30, 2025, and December 31, 2024:June 30, 2025December 31, 2024Risk-free interest rate3.63% - 4.18%4.08% - 4.23%Volatility44.10% - 59.83% 62.14% - 68.68%Dividend yield— %— %Expected term (years)0.53 - 3.401.02 - 3.89Weighted average fair value$2.88 $3.25 The following table is a reconciliation for the common stock warrant liabilities measured at fair value using Level 3 unobservable inputs (in thousands):Balance as of December 31, 2024$17,804 Change in fair value measurement of warrant liabilities(1,997)Balance as of June 30, 2025$15,807 For the six months ended June